From our analysis of the BEAT AML database using the same filters as in our study, we also observed a near-significant reduced survival probability in RAS+ ELN intermediate AML patients, even if those mutations were reported in only 19.5% of this category, as compared to 32.1% in our cohort.
← all excerpts
RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia.
1
—
—